Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum.
Cambodia
Copy number
Malaria
Piperaquine
Plasmepsin
qPCR
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
13 May 2020
13 May 2020
Historique:
received:
14
01
2020
accepted:
29
04
2020
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Long regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of Plasmodium falciparum malaria. Recently, resistance to the artemisinin combination therapy partner drug piperaquine has been observed in multiple locations across Southeast Asia. Genetic studies have identified single nucleotide polymorphisms as well as copy number variations in the plasmepsin 2 and plasmepsin 3 genes, which encode haemoglobin-degrading proteases that associate with clinical and in vitro piperaquine resistance. To accurately and quickly determine the presence of copy number variations in the plasmepsin 2/3 genes in field isolates, this study developed a quantitative PCR assay using TaqMan probes. Copy number estimates were validated using a separate SYBR green-based quantitative PCR assay as well as a novel PCR-based breakpoint assay to detect the hybrid gene product. Field samples from 2012 to 2015 across three sites in Cambodia were tested using DNA extracted from dried blood spots and whole blood to monitor the extent of plasmepsin 2/3 gene amplifications, as well as amplifications in the multidrug resistance transporter 1 gene (pfmdr1), a marker of mefloquine resistance. This study found high concordance across all methods of copy number detection. For samples derived from dried blood spots, a success rate greater than 80% was found in each assay, with more recent samples performing better. Evidence of extensive plasmepsin 2/3 copy number amplifications was observed in Pursat (94%, 2015) (Western Cambodia) and Preah Vihear (87%, 2014) (Northern Cambodia), and lower levels in Ratanakiri (16%, 2014) (Eastern Cambodia). A shift was observed from two copies of plasmepsin 2 in Pursat in 2013 to three copies in 2014-2015 (25% to 64%). Pfmdr1 amplifications were absent in all samples from Preah Vihear and Ratanakiri in 2014 and absent in Pursat in 2015. The multiplex TaqMan assay is a robust tool for monitoring both plasmepsin 2/3 and pfmdr1 copy number variations in field isolates, and the SYBR-green and breakpoint assays are useful for monitoring plasmepsin 2/3 amplifications. This study shows increasing levels of plasmepsin 2 copy numbers across Cambodia from 2012 to 2015 and a complete reversion of multicopy pfmdr1 parasites to single copy parasites in all study locations.
Sections du résumé
BACKGROUND
BACKGROUND
Long regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of Plasmodium falciparum malaria. Recently, resistance to the artemisinin combination therapy partner drug piperaquine has been observed in multiple locations across Southeast Asia. Genetic studies have identified single nucleotide polymorphisms as well as copy number variations in the plasmepsin 2 and plasmepsin 3 genes, which encode haemoglobin-degrading proteases that associate with clinical and in vitro piperaquine resistance.
RESULTS
RESULTS
To accurately and quickly determine the presence of copy number variations in the plasmepsin 2/3 genes in field isolates, this study developed a quantitative PCR assay using TaqMan probes. Copy number estimates were validated using a separate SYBR green-based quantitative PCR assay as well as a novel PCR-based breakpoint assay to detect the hybrid gene product. Field samples from 2012 to 2015 across three sites in Cambodia were tested using DNA extracted from dried blood spots and whole blood to monitor the extent of plasmepsin 2/3 gene amplifications, as well as amplifications in the multidrug resistance transporter 1 gene (pfmdr1), a marker of mefloquine resistance. This study found high concordance across all methods of copy number detection. For samples derived from dried blood spots, a success rate greater than 80% was found in each assay, with more recent samples performing better. Evidence of extensive plasmepsin 2/3 copy number amplifications was observed in Pursat (94%, 2015) (Western Cambodia) and Preah Vihear (87%, 2014) (Northern Cambodia), and lower levels in Ratanakiri (16%, 2014) (Eastern Cambodia). A shift was observed from two copies of plasmepsin 2 in Pursat in 2013 to three copies in 2014-2015 (25% to 64%). Pfmdr1 amplifications were absent in all samples from Preah Vihear and Ratanakiri in 2014 and absent in Pursat in 2015.
CONCLUSIONS
CONCLUSIONS
The multiplex TaqMan assay is a robust tool for monitoring both plasmepsin 2/3 and pfmdr1 copy number variations in field isolates, and the SYBR-green and breakpoint assays are useful for monitoring plasmepsin 2/3 amplifications. This study shows increasing levels of plasmepsin 2 copy numbers across Cambodia from 2012 to 2015 and a complete reversion of multicopy pfmdr1 parasites to single copy parasites in all study locations.
Identifiants
pubmed: 32404110
doi: 10.1186/s12936-020-03249-x
pii: 10.1186/s12936-020-03249-x
pmc: PMC7218657
doi:
Substances chimiques
Antimalarials
0
Quinolines
0
piperaquine
A0HV2Q956Y
Aspartic Acid Endopeptidases
EC 3.4.23.-
plasmepsin
EC 3.4.23.38
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM008620
Pays : United States
Organisme : Bill and Melinda Gates Foundation
ID : OPP1118166
Organisme : Medical Research Council UK
ID : G0600718
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Organisme : Department for International Development
ID : MR/M005212/1
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770/Z/09/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098051
Pays : United Kingdom
Références
Antimicrob Agents Chemother. 2012 Jul;56(7):3615-9
pubmed: 22508315
Malar J. 2019 Apr 10;18(1):126
pubmed: 30967148
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29439977
Antimicrob Agents Chemother. 2009 Dec;53(12):4968-78
pubmed: 19752273
Emerg Infect Dis. 2017 Jan;24(1):40-48
pubmed: 29260689
Trans R Soc Trop Med Hyg. 2009 Apr;103 Suppl 1:S11-4
pubmed: 19084883
Nat Med. 2016 Mar;22(3):220-1
pubmed: 26937610
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Malar J. 2019 Oct 11;18(1):338
pubmed: 31581941
Antimicrob Agents Chemother. 2013 Nov;57(11):5277-83
pubmed: 23939897
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
Curr Top Microbiol Immunol. 2005;295:275-91
pubmed: 16265895
Exp Parasitol. 1992 Jun;74(4):470-2
pubmed: 1592095
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
J Infect Dis. 1997 Dec;176(6):1590-6
pubmed: 9395372
Lancet Infect Dis. 2020 Jan;20(1):26-27
pubmed: 31876497
Trans R Soc Trop Med Hyg. 1997 Jul-Aug;91(4):456-60
pubmed: 9373654
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Front Biosci (Schol Ed). 2012 Jun 01;4:1424-48
pubmed: 22652884
PLoS Negl Trop Dis. 2016 Oct 31;10(10):e0005091
pubmed: 27798646
N Engl J Med. 2001 Jan 25;344(4):257-63
pubmed: 11172152
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
Nature. 2002 Oct 3;419(6906):498-511
pubmed: 12368864
Am J Trop Med Hyg. 1995 Jun;52(6):565-8
pubmed: 7611566
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):990-5
pubmed: 11782538
Mol Biochem Parasitol. 1995 Apr;71(1):115-25
pubmed: 7630375
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
N Engl J Med. 2014 Jul 31;371(5):484-5
pubmed: 25075853
Int J Parasitol Drugs Drug Resist. 2019 Apr;9:16-22
pubmed: 30580023
Emerg Infect Dis. 2018 Aug;24(8):
pubmed: 29798744
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2489
pubmed: 24278487
Antimicrob Agents Chemother. 2015 Aug;59(8):4631-43
pubmed: 26014942
PLoS Genet. 2008 Oct;4(10):e1000243
pubmed: 18974876